PURPOSE: Doses of growth hormone in adults with growth hormone deficiency are now lower than previously. However, it is not clear they are as effective as higher doses. The objective of this meta-analysis was to assess efficacy of low to moderate dose (LD) GH replacement on standard endpoints of GH compared to higher doses. METHODS: A meta-analysis was carried out using PubMed, Cochrane and Embase databases from 1960 to 9/23/12. Three reviewers identified randomized double-blind, placebo-controlled trials of 6 months duration. Of 173 publications, 28 representing 22 trials (591 GH-treated patients and 562 placebo) were included. Data were independently extracted by three reviewers. Endpoints were analyzed if ≥4 studies per dose group reported baseline and 6 month data. RESULTS: Mean lean body mass (LBM) increased by 2.61 kg in GH-treated subjects versus 0.04 in the placebo group (P < 0.0001). Fat mass (FM) was reduced by -2.19 kg versus 0.31 (GH vs. placebo) (P = 0.0002). Changes in LBM and FM were dose-related (P = 0.02 and 0.007, respectively), high dose (HD) being more effective than low dose (LBM P = 0.03 and FM P = 0.04). In contrast, treatment with GH reduced total cholesterol -0.38 mmol/L versus. 0.01 (placebo) (P < 0.0001), and low density lipoprotein cholesterol (LDL-C) -0.42 mmol/L versus -0.1 (P = 0.0009), but there were no differences between LD and HD GH. CONCLUSIONS: LDs of hGH improve total- and LDL-C, and body composition. Higher doses are more effective on body composition, but not lipids.
PURPOSE: Doses of growth hormone in adults with growth hormone deficiency are now lower than previously. However, it is not clear they are as effective as higher doses. The objective of this meta-analysis was to assess efficacy of low to moderate dose (LD) GH replacement on standard endpoints of GH compared to higher doses. METHODS: A meta-analysis was carried out using PubMed, Cochrane and Embase databases from 1960 to 9/23/12. Three reviewers identified randomized double-blind, placebo-controlled trials of 6 months duration. Of 173 publications, 28 representing 22 trials (591 GH-treated patients and 562 placebo) were included. Data were independently extracted by three reviewers. Endpoints were analyzed if ≥4 studies per dose group reported baseline and 6 month data. RESULTS: Mean lean body mass (LBM) increased by 2.61 kg in GH-treated subjects versus 0.04 in the placebo group (P < 0.0001). Fat mass (FM) was reduced by -2.19 kg versus 0.31 (GH vs. placebo) (P = 0.0002). Changes in LBM and FM were dose-related (P = 0.02 and 0.007, respectively), high dose (HD) being more effective than low dose (LBM P = 0.03 and FM P = 0.04). In contrast, treatment with GH reduced total cholesterol -0.38 mmol/L versus. 0.01 (placebo) (P < 0.0001), and low density lipoprotein cholesterol (LDL-C) -0.42 mmol/L versus -0.1 (P = 0.0009), but there were no differences between LD and HD GH. CONCLUSIONS: LDs of hGH improve total- and LDL-C, and body composition. Higher doses are more effective on body composition, but not lipids.
Authors: C M Hwu; C F Kwok; T Y Lai; K C Shih; T S Lee; L C Hsiao; S H Lee; V S Fang; L T Ho Journal: J Clin Endocrinol Metab Date: 1997-10 Impact factor: 5.958
Authors: Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance Journal: J Clin Endocrinol Metab Date: 2011-06 Impact factor: 5.958
Authors: A Colao; C di Somma; A Cuocolo; L Spinelli; N Tedesco; R Pivonello; D Bonaduce; M Salvatore; G Lombardi Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: Natasha M Appelman-Dijkstra; Kim M J A Claessen; Ferdinand Roelfsema; Alberto M Pereira; Nienke R Biermasz Journal: Eur J Endocrinol Date: 2013-05-28 Impact factor: 6.664
Authors: Lara Pena-Bello; Sonia Pértega-Diaz; Susana Sangiao-Alvarellos; Elena Outeiriño-Blanco; Raquel Eiras-Leal; Bárbara Varela-Rodriguez; Paula Juiz-Valiña; Miguel Pérez-Fontán; María Cordido; Fernando Cordido Journal: PLoS One Date: 2016-07-29 Impact factor: 3.240
Authors: Charlotte Höybye; Andreas F H Pfeiffer; Diego Ferone; Jens Sandahl Christiansen; David Gilfoyle; Eva Dam Christoffersen; Eva Mortensen; Jonathan A Leff; Michael Beckert Journal: Endocr Connect Date: 2017-02-14 Impact factor: 3.335
Authors: Rachel K Rowe; Benjamin M Rumney; Hazel G May; Paska Permana; P David Adelson; S Mitchell Harman; Jonathan Lifshitz; Theresa C Thomas Journal: Endocr Connect Date: 2016-06-17 Impact factor: 3.335